Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: April-18-07
Credit Expiration Date: September-30-08

Faculty

James M. Scheiman, MD
Professor of Medicine
Division of Gastroenterology
University of Michigan
Ann Arbor, Michigan

Michael P. Slyk, PharmD, FASCP
President
Pharmacotherapy Associates, Inc.
Boardman, Ohio

Credit Hours

1

Medium

Podcast (MP3 & PDF)

Program Description

THIS ACTIVITY WAS ORIGINALLY PRESENTED AS A LIVE AUDIOCONFERENCE BEGINNING ON April 18, 2007 AND AS AN ONLINE ACTIVITY. IF YOU EARNED CME OR CE CREDIT FOR THE AUDIOCONFERENCE OR ONLINE RELEASE YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR PODCAST.

Over the last two decades, the use of low-dose aspirin has emerged as an important risk factor for complicated peptic ulcers—a condition that can cause significant morbidity and mortality in nursing facility and assisted living residents. One to two percent of residents on aspirin prophylaxis will have some type of serious gastrointestinal (GI) complication, including bleeding and perforation. Residents of long-term care facilities may be especially prone to ulcer bleeding and perforation since they may also require anticoagulants for other medical conditions, such as venous thromboembolism prophylaxis or treatment. Because symptoms are subtle or atypical in the elderly, even with severe disease, diagnosis and treatment are often delayed.

Fortunately, ulcer complications associated with aspirin and other nonsteroidal anti-inflammatory drug (NSAID) use are predictable and avoidable. Clinicians that are mindful of the senior population’s increased risk for GI adverse events can initiate treatment to prevent complications. This program will help participants to develop an interdisciplinary approach to identifying residents who are at-risk for developing peptic ulcer disease and initiate management strategies for reducing the disease and associated complications.

Program Developer/Facilitator


.

Target Audience

This program has been developed specifically for healthcare professionals caring for senior patients at-risk for peptic ulcer disease.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe the risk factors for peptic ulcer development and complications.
  2. Review management strategies to reduce ulcer development in the elderly taking aspirin or other NSAIDs.
  3. Summarize pharmacologic regimens used to treat and prevent peptic ulcer disease.
  4. Describe how an interdisciplinary team approach involving physicians, pharmacists, nurse practitioners, and nurses can optimize care for patients in skilled nursing facilities.

Disclosures

It is the policy of ASCP, in accordance with the guidelines set forth by the Accreditation Council for Pharmacy Education, and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by ASCP and AKH prior to accreditation of the activity.

The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speakers’ interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

James M. Scheiman, MD, discloses that he is a consultant for AstraZeneca, Merck and Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Pozen, Inc., Bayer Corporation, GlaxoSmithKline, PLx Pharma, Inc., NiCox, and Horizon Therapeutics. He has received speakers’ fees from AstraZeneca, Takeda Pharmaceuticals North America, Inc. and Santarus, Inc.

Michael P. Slyk, PharmD, FASCP, discloses that he is a product consultant for Janssen Pharmaceutica Inc.

Credit Statements

Pharmacists: ASCP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is accredited for 1.0 contact hour (0.1 CEUs) of continuing education credit. Universal program number 203-999-07-050-H01.

Nurses: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation # 1087. This program has been approved for 1 contact hour by NADONA/LTC.

Nurse Practitioners: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 1 contact hour which includes 1 pharmacology contact hour.

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media.

AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release Date: April 18, 2007

Credit will be awarded upon submission of a completed program evaluation and a post-test with a passing grade of 70% or better.

Commercial Support Statements

Supported by an educational grant from AstraZeneca.

Instructions

This program consists of an MP3 audio file and a PDF workbook file containing slide images and the post-test and evaluation. This activity will require approximately 60 minutes to complete.

  1. Print a copy of the PDF workbook file.
  2. Follow the slides in the workbook while listening to the audio file on your computer or your MP3 player.
  3. Upon completion of the program, complete the post-test and evaluation found on the last two pages of the workbook, or follow the link to the online post-test. Instructions for submitting the post-test can be found on the post-test form. Successful completion (70% or better) online will enable you to immediately print a statement of credit. If you elect to mail the printed post-test and evaluation a certificate of credit for satisfactory completion will be mailed within 4 to 6 weeks.

Certificate Fee

$0.00

Disclaimer

©2007, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and audioconference are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., the American Society of Consultant Pharmacists, the National Association of Directors of Nursing Administration in Long-Term Care, or AstraZeneca. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS